JPRN-UMIN000035046招募中未知
Efficacy and safety of TAF prophylactic administration for HBV reactivation hepatitis during immunosuppressive or anti-tumor therap - TAF for prevention of HBV reactivation
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with a past history of hypersensitivity to TAF 2) Patients with serious liver dysfunction (Child-Pugh Class B or C) 3) Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4) Liver transplantation 5) Patients who are not expected to be survived more than 12 month by the primary physician. 6) Other patients judged to be inappropriate to participate in the study by the primary physician
研究者
相似试验
尚未招募
2 期
The Women TAF-FTC Benchmark Study.HIV/AIDSPACTR202209528604242niversity of Washington54
招募中
3 期
A study to find the effect of Tofacitinib film forming lotion compared to mometasone solution in baldhead patientsCTRI/2024/01/061349Hetero Healthcare Limited
已完成
1 期
An academic trial to study the prophylactic activity of Vishasura Kudineer(VSK)in healthcare workers exposed/non-exposed to COVID-19 patients.CTRI/2020/11/028905Ministry of AYUSH120
招募中
不适用
Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis.Chronic hepatitis B and cirrhosisJPRN-UMIN000034362ippon Medical Chiba Hokusoh Hospital500
进行中（未招募）
1 期
Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF)HIV infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003345-29-GBKings College Hospital NHS Foundation Trust40